CalciMedica Inc. (CALC)
(Delayed Data from NSDQ)
$4.08 USD
+0.12 (3.04%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $4.14 +0.06 (1.47%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.08 USD
+0.12 (3.04%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $4.14 +0.06 (1.47%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Zacks News
Strength in Kidney Care Likely to Aid DaVita's (DVA) Q2 Earnings
by Zacks Equity Research
Improvement in RPT and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the second quarter.
Does CalciMedica Inc. (CALC) Have the Potential to Rally 232.3% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 232.3% upside potential for CalciMedica Inc. (CALC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Is Alcon (ALC) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Alcon (ALC) and CalciMedica Inc. (CALC) have performed compared to their sector so far this year.